Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma (IO102-IO103-013 / MK3475-D18)

NCT05155254 is registered in ClinicalTrials.gov with IO Biotech as lead sponsor.

NCT NCT05155254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05155254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma (IO102-IO103-013 / MK3475-D18)
Lead sponsor
IO Biotech
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 17, 2022
Completion date
September 30, 2027
Enrollment
407 (actual)
Sites
112

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma, unresectable melanoma